Oppenheimer Holdings Inc. set a $94.00 price target on Medtronic PLC (NYSE:MDT) in a research report released on Tuesday. The brokerage currently has a buy rating on the medical technology company’s stock.

MDT has been the topic of several other reports. Needham & Company LLC increased their price objective on Medtronic PLC from $93.00 to $95.00 and gave the company a buy rating in a research report on Thursday, August 25th. Vetr cut Medtronic PLC from a strong-buy rating to a buy rating and set a $91.28 price objective on the stock. in a research report on Monday. Jefferies Group reaffirmed a buy rating and set a $93.00 price objective on shares of Medtronic PLC in a research report on Thursday, August 25th. Cowen and Company set a $94.00 target price on Medtronic PLC and gave the stock a buy rating in a research report on Tuesday, August 23rd. Finally, Credit Suisse Group AG reissued an outperform rating and issued a $92.00 target price on shares of Medtronic PLC in a research report on Thursday, August 25th. Seven equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $89.31.

Analyst Recommendations for Medtronic PLC (NYSE:MDT)

Shares of Medtronic PLC (NYSE:MDT) traded up 1.4527% on Tuesday, hitting $74.6692. The stock had a trading volume of 5,816,355 shares. The stock has a market capitalization of $103.19 billion, a P/E ratio of 29.0542 and a beta of 1.01. The firm has a 50-day moving average price of $82.54 and a 200-day moving average price of $84.78. Medtronic PLC has a 52 week low of $71.03 and a 52 week high of $89.27.

Medtronic PLC (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 22nd. The medical technology company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.11 by $0.01. Medtronic PLC had a return on equity of 12.06% and a net margin of 12.70%. The company had revenue of $7.35 billion for the quarter, compared to analysts’ expectations of $7.46 billion. During the same period last year, the firm posted $1.03 earnings per share. Medtronic PLC’s revenue was up 4.1% compared to the same quarter last year. Equities analysts expect that Medtronic PLC will post $4.66 earnings per share for the current fiscal year.

In related news, CEO Omar Ishrak sold 61,925 shares of the business’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $84.93, for a total transaction of $5,259,290.25. Following the completion of the transaction, the chief executive officer now owns 565,916 shares in the company, valued at approximately $48,063,245.88. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Richard Kuntz sold 25,199 shares of the business’s stock in a transaction on Monday, September 26th. The shares were sold at an average price of $86.67, for a total value of $2,183,997.33. Following the transaction, the vice president now owns 149,425 shares of the company’s stock, valued at approximately $12,950,664.75. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Krilogy Financial LLC boosted its position in Medtronic PLC by 35.2% in the second quarter. Krilogy Financial LLC now owns 1,163 shares of the medical technology company’s stock worth $101,000 after buying an additional 303 shares during the last quarter. Motco boosted its stake in shares of Medtronic PLC by 70.9% in the third quarter. Motco now owns 1,350 shares of the medical technology company’s stock valued at $117,000 after buying an additional 560 shares in the last quarter. TLP Group LLC purchased a new stake in shares of Medtronic PLC during the third quarter valued at $124,000. Birch Hill Investment Advisors LLC purchased a new stake in shares of Medtronic PLC during the third quarter valued at $128,000. Finally, Proficio Capital Partners LLC boosted its stake in shares of Medtronic PLC by 44.5% in the second quarter. Proficio Capital Partners LLC now owns 1,497 shares of the medical technology company’s stock valued at $131,000 after buying an additional 461 shares in the last quarter. Institutional investors own 81.25% of the company’s stock.

WARNING: “Medtronic PLC (MDT) Given a $94.00 Price Target at Oppenheimer Holdings Inc.” was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2016/11/23/medtronic-plc-mdt-given-a-94-00-price-target-at-oppenheimer-holdings-inc.html.

Medtronic PLC Company Profile

Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

5 Day Chart for NYSE:MDT

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.